PMID- 23440904
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130227
LR  - 20211021
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 7
DP  - 2013
TI  - Preference for a fixed combination of brinzolamide/timolol versus 
      dorzolamide/timolol among patients with open-angle glaucoma or ocular 
      hypertension.
PG  - 357-62
LID - 10.2147/OPTH.S38575 [doi]
AB  - OBJECTIVE: To assess ocular discomfort upon instillation and patient preference 
      for brinzolamide/timolol relative to dorzolamide/timolol, in patients with 
      open-angle glaucoma or ocular hypertension. METHODS: This was a multicenter, 
      prospective, patient-masked, randomized, crossover study. On day 0, patients 
      received one drop of brinzolamide/timolol in one eye and one drop of 
      dorzolamide/timolol in the contralateral eye. On day 1, patients were randomly 
      assigned to receive one drop of either brinzolamide/timolol or 
      dorzolamide/timolol in both eyes; on day 2, patients received one drop of the 
      alternate treatment in both eyes. Measures included a patient preference question 
      on day 2 (primary) and mean ocular discomfort scale scores on days 1 and 2 
      (secondary). Safety assessments included adverse events, visual acuity, and 
      slit-lamp examinations. RESULTS: Of 120 patients who enrolled, 115 completed the 
      study. Of these, 112 patients instilled both medications and expressed a study 
      medication preference on day 2. A significantly greater percentage preferred 
      brinzolamide/timolol to dorzolamide/timolol (67.0% versus 30.4%; P < 0.001). The 
      ocular discomfort (expressed as mean [standard deviation]) with 
      brinzolamide/timolol was significantly lower than with dorzolamide/timolol (day 
      2:1.9 [2.3] versus 3.7 [2.8], respectively [P = 0.0003]; both days combined: 2.1 
      [2.5] versus 3.5 [2.9], respectively [P = 0.00014]). On day 1, five patients 
      receiving brinzolamide/timolol reported five nonserious adverse events (AEs): flu 
      (n = 1), bitter taste (n = 2), and headache (n = 2). Four events, bitter taste 
      (two events) and headache (two events), were considered related to 
      brinzolamide/timolol. Events were mild in intensity, except bitter taste of 
      moderate intensity reported by one patient. No AEs were reported at day 2. All 
      AEs resolved without additional treatment. No clinically relevant changes from 
      baseline were observed in best-corrected visual acuity or slit-lamp examinations 
      of ocular signs. CONCLUSION: Patients had less discomfort with 
      brinzolamide/timolol than with dorzolamide/timolol, and more expressed a 
      preference for brinzolamide/timolol. Both treatments were generally safe and well 
      tolerated.
FAU - Sanseau, Ana
AU  - Sanseau A
AD  - Instituto de la Vision, Ciudad de Buenos Aires, Argentina.
FAU - Sampaolesi, Juan
AU  - Sampaolesi J
FAU - Suzuki, Emilio Rintaro Jr
AU  - Suzuki ER Jr
FAU - Lopes, Joao Franca
AU  - Lopes JF
FAU - Borel, Hector
AU  - Borel H
LA  - eng
PT  - Journal Article
DEP - 20130218
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC3578670
OTO - NOTNLM
OT  - brinzolamide
OT  - dorzolamide
OT  - fixed combination
OT  - ocular discomfort
OT  - patient preference
OT  - timolol
EDAT- 2013/02/27 06:00
MHDA- 2013/02/27 06:01
PMCR- 2013/02/18
CRDT- 2013/02/27 06:00
PHST- 2013/02/27 06:00 [entrez]
PHST- 2013/02/27 06:00 [pubmed]
PHST- 2013/02/27 06:01 [medline]
PHST- 2013/02/18 00:00 [pmc-release]
AID - opth-7-357 [pii]
AID - 10.2147/OPTH.S38575 [doi]
PST - ppublish
SO  - Clin Ophthalmol. 2013;7:357-62. doi: 10.2147/OPTH.S38575. Epub 2013 Feb 18.